journal article·2019-07Open access

Microfluidic Multitissue Platform for Advanced Embryotoxicity Testing In Vitro

Julia Alicia Boos, Patrick Mark Misun, Astrid Michlmayr, Andreas Hierlemann, Olivier Frey

Advanced Science· Volume 6· Issue 13

Abstract

Abstract The integration of metabolic competence in developmental toxicity assays in vitro is of fundamental importance to better predict adverse drug effects. Here, a microfluidic hanging‐drop platform is presented that seamlessly integrates liver metabolism into the embryonic stem cell test (EST). Primary human liver microtissues (hLiMTs) and embryoid bodies (EBs) are combined in the same fluidic network, so that hLiMT‐generated metabolites are directly transported to the EBs. Gravity‐driven flow through the network enables continuous intertissue communication, constant medium turnover, and, most importantly, immediate exchange of metabolites. As a proof of concept, the prodrug cyclophosphamide is investigated and a fourfold lower ID50 concentration (50% inhibition of EB differentiation) is found after biotransformation, which demonstrates the potentially adverse effects of metabolites on embryotoxicity. The metaEST platform provides a promising tool to increase the predictive power of the current EST assay by more comprehensively including and better reflecting physiological processes in in vitro tests.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Microfluidic and Bio-sensing Technologies · Pluripotent Stem Cells Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Bioengineering Laboratory Department of Biosystems Science and Engineering ETH Zürich Mattenstrasse 26 4058 Basel Switzerland

InSphero AG Wagistrasse 27 8952 Schlieren Switzerland

Funding

Eidgenössische Technische Hochschule Zürich

References (44)

Show source-provided references
1. 10.1021/acs.chemrestox.5b0045810.1021/acs.chemrestox.5b00458 ↗
2. 10.1016/B978-0-12-385212-0.00012-310.1016/B978-0-12-385212-0.00012-3 ↗
3. 10.1016/B978-0-12-382032-7.10008-610.1016/B978-0-12-382032-7.10008-6 ↗
4. 10.1038/4601080a10.1038/4601080a ↗
5. International Council for Harmonization · Draft ICH Harmon. Guidel. S5(R3) · 2017 · 5 · 63
6. Nuffield Council on BioEthics · 2005
7. 10.1002/bdr2.121210.1002/bdr2.1212 ↗
8. EC · 2003
9. 10.1016/j.reprotox.2017.05.00610.1016/j.reprotox.2017.05.006 ↗
10. Ellis‐Hutchings R. G. · 2011 · 409
11. 10.1177/02611929040320030510.1177/026119290403200305 ↗
12. 10.1177/02611929040320030610.1177/026119290403200306 ↗
13. 10.1177/02611929040320030710.1177/026119290403200307 ↗
14. 10.1038/nprot.2011.34810.1038/nprot.2011.348 ↗
15. 10.3109/10408444.2012.67448310.3109/10408444.2012.674483 ↗
16. 10.1177/02611929020300020410.1177/026119290203000204 ↗
17. 10.1177/02611929060340011310.1177/026119290603400113 ↗
18. 10.1177/02611929060340050410.1177/026119290603400504 ↗
19. 10.1146/annurev.pa.29.040189.00112110.1146/annurev.pa.29.040189.001121 ↗
20. 10.1016/S0041-008X(03)00128-510.1016/S0041-008X(03)00128-5 ↗
21. 10.1089/ten.teb.2016.003110.1089/ten.teb.2016.0031 ↗
22. 10.1177/02611929090370031410.1177/026119290903700314 ↗
23. 10.1016/0300-483X(95)03082-Q10.1016/0300-483X(95)03082-Q ↗
24. 10.1111/j.1600-0773.1991.tb00408.x10.1111/j.1600-0773.1991.tb00408.x ↗
25. 10.1177/02611929020300010810.1177/026119290203000108 ↗
26. Binder M. · 2008
27. 10.1016/j.reprotox.2010.01.00910.1016/j.reprotox.2010.01.009 ↗
28. Bach P. H. · ATLA, Altern. Lab. Anim. · 1996 · 24 · 89310.1177/026119299602400605 ↗
29. Liu Y. · Curr. Protoc. Pharmacol. · 2004 · 26 · 7.9.1
30. 10.1093/toxsci/kfx28910.1093/toxsci/kfx289 ↗
31. 10.1038/nrm223610.1038/nrm2236 ↗
32. 10.1002/jcp.2468310.1002/jcp.24683 ↗
33. 10.1089/aivt.2017.002210.1089/aivt.2017.0022 ↗
34. 10.1038/nature0506310.1038/nature05063 ↗
35. 10.1002/adhm.20170041910.1002/adhm.201700419 ↗
36. 10.1039/b915147h10.1039/b915147h ↗
37. 10.1016/j.jbiotec.2015.02.00210.1016/j.jbiotec.2015.02.002 ↗
38. 10.4155/fsoa-2017-000210.4155/fsoa-2017-0002 ↗
39. 10.1038/ncomms525010.1038/ncomms5250 ↗
40. Hales B. F. · Cancer Res. · 1982 · 42 · 3016
41. 10.1016/S0006-2952(99)00410-410.1016/S0006-2952(99)00410-4 ↗
42. Domeyer B. E. · Cancer Res. · 1980 · 40 · 174
43. 10.2165/00003088-200544110-0000310.2165/00003088-200544110-00003 ↗
44. 10.1016/S0378-4347(01)00279-110.1016/S0378-4347(01)00279-1 ↗